학술논문

Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: Evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)
Document Type
Journal
Source
EUROPEAN JOURNAL OF CANCER; SEP 1999, 35 pS68-pS68, 1p. Supplement: 4
Subject
Language
English
ISSN
09598049